| Identification | Back Directory | [Name]
4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- | [CAS]
2055496-11-0 | [Synonyms]
ABBV-157
Cedirogant
4-Piperidineacetic acid, 1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)-1H-indol-1-yl]methyl]benzoyl]- | [Molecular Formula]
C24H20Cl3F3N2O3 | [MDL Number]
MFCD34567687 | [MOL File]
2055496-11-0.mol | [Molecular Weight]
547.78 |
| Chemical Properties | Back Directory | [Boiling point ]
714.4±60.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (456.39 mM; Need ultrasonic) | [form ]
Solid | [pka]
4.66±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research[1][2]. | [storage]
Store at -20°C | [References]
[1] Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737. DOI:10.2147/JEP.S265632
[2] Christian Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin Drug Discov. 2021 Jul 7;1-19. DOI:10.1080/17460441.2021.1948833 |
|
|